BACKGROUND: It has been postulated that Multiple sclerosis (MS) stems from a 
narrowing in the veins that drain blood from the brain, known medically as 
chronic cerebrospinal venous insufficiency, or CCSVI. It has been proposed that 
balloon angioplasty should alleviate the symptoms of MS. This procedure is also 
known as The "Liberation Procedure". Accordingly, a clinical study was 
undertaken to determine the effects of dexmedetomidine in patients undergoing 
the liberation procedure.
AIMS: To assess the effectiveness of dexmedetomidine in providing adequate 
sedation and pain relief for patients undergoing the liberation procedure.
SETTINGS AND DESIGN: A prospective, nonrandomized observational study of 60 
consecutive adult patients undergoing the liberation procedure under monitored 
anesthesia care (MAC) who will receive dexmedetomidine as an anesthetic agent.
METHODS: A total of 60 adult patients were enrolled in the study. 
Dexmedetomidine was administered to all patients in a loading dose of 1 mcg/kg, 
which was followed by a maintenance dose of 0.2-0.5 mcg/kg/h. The evaluation of 
quality of sedation was based on Ramsay Sedation and the quality of analgesia 
was assessed using the visual analog scale. The following parameters were 
measured continuously: heart rate, mean arterial pressure and hemoglobin oxygen 
saturation. Patients were asked to answer the question, "How would you rate your 
experience with the sedation you have received during surgery?" using a 
seven-point Likert-like verbal rating scale.
STATISTICAL ANALYSIS: Repeated measurements were analyzed by repeated measures 
ANOVA for HR and BP.
RESULTS: Most of our patients were satisfied with their sedation. In most of the 
patients, MAP and HR dropped after the bolus dose of dexmedetomidine, and the 
drop was statistically significant.
CONCLUSIONS: Dexmedetomidine can be used as a sole sedative agent in patients 
undergoing the liberation procedure.